Search

The coronavirus disease 2019 (COVID-19) pandemic has revolutionized the priorities of the medical society worldwide. Although most patients infected with SARS-CoV-2 exhibit respiratory symptoms, other organs may also be involved, including the liver, often resulting in liver injury. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its prevalence is expected to increase together with the epidemics of type 2 diabetes and obesity. Data about liver injury during COVID-19 are numerous, while overviews of this infection in patients with NAFLD, both in terms of respiratory and liver, are emerging. In this review, we summarise the current research focusing on COVID-19 in NAFLD patients and discuss the association between liver injury in COVID-19 subjects and non-alcoholic fatty liver disease.

Type 2 diabetes mellitus is one of the most common comorbidities associated with COVID-19. Furthermore, people with type 2 diabetes infected with SARS-CoV-2 have higher hospitalization and mortality rates [1]. Most publications do not distinguish between type 1 and type 2 diabetes, so evidence relating to the spread of COVID-19 infection in type 1 diabetes is limited, but new data are emerging.